FIELD: medicine.
SUBSTANCE: what is presented is using Histochrom (same as echinochrome A or pentahydroxyethyl naphthoquinone) as an agent able to prevent pulmonary fibrosis developed under cytostatic agents. The invention can be used for the pharmacological prevention and correction of the pulmonary tissue disorders caused by administering the cytostatic agents.
EFFECT: preventing hypertrophy of interalveolar connective tissue in the lungs associated with administering bleomycin.
4 dwg, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
AGENT PREVENTING DEVELOPING DISORDERS IN PULMONARY TISSUE AND BLOOD SYSTEM ACCOMPANYING CYTOSTATIC ACTION | 2011 |
|
RU2464983C1 |
PREPARATION PREVENTING DEVELOPMENT OF ABNORMALITIES IN LUNG TISSUE UNDER CYTOSTATIC IMPACT | 2011 |
|
RU2455991C1 |
AGENT POSSESSING ANTI-INFLAMMATORY AND ANTIFIBROTIC ACTION IN PULMONARY TISSUE, AND CYTOSTATIC ACTION | 2013 |
|
RU2530651C1 |
AGENT POSSESSING ANTI-INFLAMMATORY AND ANTIFIBROTIC ACTION IN PULMONARY TISSUE, AND CYTOSTATIC ACTION | 2012 |
|
RU2479312C1 |
METHOD OF TREATING PULMONARY FIBROSIS | 2012 |
|
RU2494470C1 |
WAY OF MODELLING OF CHRONIC OBSTRUCTIVE DISEASE OF LUNGS | 2008 |
|
RU2360296C1 |
METHOD FOR IMPROVING THERAPEUTIC EFFECTIVENESS IN LUNG TISSUE DISORDERS AFTER ACTION OF CYTOSTATICS | 2012 |
|
RU2497523C1 |
PHARMACEUTICAL COMPOSITION BASED ON GLUCOCORTICOSTEROID BUDESONIDE AND PHOSPHATIDYLCHOLINE FOR DRY INHALATION | 2019 |
|
RU2730488C1 |
METHOD FOR SIMULATING ANTHRACOSILICOSIS | 2013 |
|
RU2534872C1 |
ANTIOXIDANTS COMPOSITION SUITABLE FOR ORAL ADMINISTRATION IN THERAPY OF INFLAMMATORY PROCESS IN LUNGS | 2018 |
|
RU2684783C1 |
Authors
Dates
2015-06-27—Published
2013-12-16—Filed